$SYRE
Spyre Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000163628224000051 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $0.00 $688.0K
YoY Change -100.0% 10.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.65M $11.51M $7.439M
YoY Change 24.1% 54.74% -3.07%
% of Gross Profit
Research & Development $44.74M $32.64M $17.39M
YoY Change 81.44% 87.71% 13.09%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $360.0K
YoY Change -100.0% -4.76%
% of Gross Profit
Operating Expenses $55.39M $44.15M $159.9M
YoY Change 202.08% -72.4% 593.92%
Operating Profit -$55.39M -$44.15M -$159.2M
YoY Change 202.08% -72.28% 610.19%
Interest Expense $5.184M $5.920M -$57.82M
YoY Change -121.5% -110.24% -55696.15%
% of Operating Profit
Other Income/Expense, Net -$13.62M $5.310M -$57.83M
YoY Change -37.44% -109.18% -53153.21%
Pretax Income -$69.01M -$38.84M -$217.1M
YoY Change 72.08% -82.11% 872.82%
Income Tax $18.00K $0.00 $7.000K
% Of Pretax Income
Net Earnings -$69.03M -$38.84M -$217.1M
YoY Change 72.11% -82.11% 872.45%
Net Earnings / Revenue -31552.47%
Basic Earnings Per Share -$1.36 -$0.86 -$2.27
Diluted Earnings Per Share -$1.36 -$0.86 -$2.27
COMMON SHARES
Basic Shares Outstanding 50.79M shares 40.28M shares 65.40M
Diluted Shares Outstanding 50.89M shares 45.32M shares 95.57M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $414.2M $426.0M $235.4M
YoY Change 103.45% 80.97% 165.84%
Cash & Equivalents $71.58M $45.14M $235.4M
Short-Term Investments $342.6M $380.9M $0.00
Other Short-Term Assets $6.852M $9.741M $2.882M
YoY Change 211.45% 237.99% -62.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $421.1M $435.7M $239.9M
YoY Change 104.46% 81.64% 148.21%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 11.11% 0.0% -98.67%
Total Long-Term Assets $10.00K $331.0K $3.643M
YoY Change -99.24% -90.91% -63.79%
TOTAL ASSETS
Total Short-Term Assets $421.1M $435.7M $239.9M
Total Long-Term Assets $10.00K $331.0K $3.643M
Total Assets $421.1M $436.1M $243.5M
YoY Change 103.16% 79.06% 128.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.65M $13.80M $2.854M
YoY Change -8.62% 383.5% 45.76%
Accrued Expenses $13.15M $5.683M $32.76M
YoY Change -17.28% -82.65% 140.64%
Deferred Revenue $3.271M
YoY Change 22.83%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.54M $22.12M $232.2M
YoY Change 28.23% -90.47% 1364.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.16M $39.56M $21.34M
YoY Change 74.69% 85.37%
Total Long-Term Liabilities $36.16M $39.56M $21.34M
YoY Change 74.69% 85.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.54M $22.12M $232.2M
Total Long-Term Liabilities $36.16M $39.56M $21.34M
Total Liabilities $93.70M $61.68M $253.6M
YoY Change 42.92% -75.68% 1024.5%
SHAREHOLDERS EQUITY
Retained Earnings -$916.1M -$847.1M -$661.1M
YoY Change 30.65% 28.13% 70.12%
Common Stock $1.086B $1.066B $453.7M
YoY Change 138.23% 134.98% -4.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $327.4M $374.4M -$207.4M
YoY Change
Total Liabilities & Shareholders Equity $421.1M $436.1M $243.5M
YoY Change 103.16% 79.06% 128.22%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$69.03M -$38.84M -$217.1M
YoY Change 72.11% -82.11% 872.45%
Depreciation, Depletion And Amortization $0.00 $0.00 $360.0K
YoY Change -100.0% -4.76%
Cash From Operating Activities -$29.42M -$62.25M -$16.64M
YoY Change -14.94% 274.02% -19.49%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $42.74M -$120.5M $6.760M
YoY Change -143.78% -1882.81% 801.33%
Cash From Investing Activities $42.74M -$120.5M $6.760M
YoY Change -143.78% -1882.81% 801.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.78M 360.0K 210.0M
YoY Change -202.0% -99.83% 390.59%
NET CHANGE
Cash From Operating Activities -29.42M -62.25M -16.64M
Cash From Investing Activities 42.74M -120.5M 6.760M
Cash From Financing Activities 12.78M 360.0K 210.0M
Net Change In Cash 26.10M -182.4M 200.1M
YoY Change -118.03% -191.15% 774.56%
FREE CASH FLOW
Cash From Operating Activities -$29.42M -$62.25M -$16.64M
Capital Expenditures $0.00
Free Cash Flow -$16.64M
YoY Change -19.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36057109 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
152269000 usd
CY2024Q1 syre Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
4390000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
16000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-681000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-43857000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36057109 shares
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
44147000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
159934000 usd
us-gaap Operating Expenses
OperatingExpenses
91921000 usd
us-gaap Operating Expenses
OperatingExpenses
178938000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44147000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-159246000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-91921000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-178052000 usd
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
5920000 usd
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
350000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
10352000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
770000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-610000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1093000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-80000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5310000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57828000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9259000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57480000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38837000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-217074000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82662000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-235532000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-29000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38837000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000 usd
us-gaap Net Income Loss
NetIncomeLoss
-82694000 usd
us-gaap Net Income Loss
NetIncomeLoss
-235503000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-56.79
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-56.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-62.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-62.03
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45316264 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45316264 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3822605 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3822605 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3796699 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3796699 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38837000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000 usd
us-gaap Net Income Loss
NetIncomeLoss
-82694000 usd
us-gaap Net Income Loss
NetIncomeLoss
-235503000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
20000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
28000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-194000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-875000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
31000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39027000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-217064000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83549000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-235444000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
184016000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8385000 usd
CY2024Q2 syre Stock Issued During Period Value Conversion Of Convertible Securities Resulting From Shareholder Approval
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesResultingFromShareholderApproval
253405000 usd
CY2024Q2 syre Stock Issued During Period Value Exchange Of Convertible Securities
StockIssuedDuringPeriodValueExchangeOfConvertibleSecurities
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2024Q2 syre Stock Issued During Period Value Options Exercised In Connection With Warrants
StockIssuedDuringPeriodValueOptionsExercisedInConnectionWithWarrants
1000 usd
CY2024Q2 syre Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
494000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7243000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-194000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38837000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
374385000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
50305000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
33652000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
3768000 usd
CY2023Q2 syre Contingent Value Right Distribution To Common Stockholders
ContingentValueRightDistributionToCommonStockholders
-29500000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1775000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-207369000 usd
us-gaap Profit Loss
ProfitLoss
-82694000 usd
us-gaap Profit Loss
ProfitLoss
-235503000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
22517000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3620000 usd
syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130486000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2580000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-915000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5984000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
123000 usd
syre Interest Proceeds Debt Securities
InterestProceedsDebtSecurities
124000 usd
syre Interest Proceeds Debt Securities
InterestProceedsDebtSecurities
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
220000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2335000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2045000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7623000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1058000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-12906000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
1247000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7489000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3368000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
575000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1271000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-298000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90790000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34277000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
105626000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
331107000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3035000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
475000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-225481000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24510000 usd
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
1430000 usd
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4885000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
172525000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
210002000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-143750000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
200259000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189215000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36416000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45465000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236675000 usd
syre Exchange Of Stock Amount Exchanged
ExchangeOfStockAmountExchanged
38502000 usd
syre Exchange Of Stock Amount Exchanged
ExchangeOfStockAmountExchanged
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
244010000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
syre Asset Acquisition Consideration Transferred Transaction Cost Incurred But Not Yet Paid
AssetAcquisitionConsiderationTransferredTransactionCostIncurredButNotYetPaid
0 usd
syre Asset Acquisition Consideration Transferred Transaction Cost Incurred But Not Yet Paid
AssetAcquisitionConsiderationTransferredTransactionCostIncurredButNotYetPaid
2067000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45144000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235358000 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
321000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
1317000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45465000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236675000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
syre Proceeds From Raising Capital
ProceedsFromRaisingCapital
1100000000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-847100000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
426300000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations or balance sheets.</span></div>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
43377000 usd
CY2024Q2 syre Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
0 usd
CY2024Q2 syre Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0 usd
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
43377000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381443000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
81000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
673000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
380851000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
186563000 usd
CY2023Q4 syre Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
6000 usd
CY2023Q4 syre Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
186569000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
150101000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
284000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
150384000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
309201000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
673000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
309201000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
673000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14738000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
14738000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000 usd
CY2024Q2 syre Number Of Domestic Banking Institutions
NumberOfDomesticBankingInstitutions
2 bank
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
270799000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
115784000 usd
CY2024Q2 syre Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
110052000 usd
CY2023Q4 syre Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
34600000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
380851000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
150384000 usd
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2664000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4054000 usd
CY2024Q2 syre Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2269000 usd
CY2023Q4 syre Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
7092000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
515000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1474000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
235000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
488000 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5683000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13108000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
387695 shares
CY2024Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
36.42
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2536697 shares
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1432353 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2714317 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.75
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8682000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1911000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22517000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3620000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
8700000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
22500000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1900000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3600000 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2024Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
45214616 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
2711439 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
40738639 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
2663408 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
101648 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1111166 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
175824 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1133291 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45316264 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45316264 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3822605 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3822605 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40914463 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40914463 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3796699 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3796699 shares
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
us-gaap Severance Costs1
SeveranceCosts1
6400000 usd
CY2023Q2 us-gaap Severance Costs1
SeveranceCosts1
6400000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
1000000.0 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
500000 usd
CY2023Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
900000 usd
CY2023Q2 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
1700000 usd
CY2023Q3 syre Operating Lease Termination Fee Amount
OperatingLeaseTerminationFeeAmount
2000000.0 usd
CY2023Q4 syre Restructuring Cost Liability
RestructuringCostLiability
1100000 usd
CY2024Q2 syre Restructuring Cost Liability
RestructuringCostLiability
0 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001636282-24-000051-index-headers.html Edgar Link pending
0001636282-24-000051-index.html Edgar Link pending
0001636282-24-000051.txt Edgar Link pending
0001636282-24-000051-xbrl.zip Edgar Link pending
ex103finalredactedparagon-.htm Edgar Link pending
ex104tl1aspy002licenseagre.htm Edgar Link pending
ex105secondamendedandresta.htm Edgar Link pending
ex106formofstockoptionagre.htm Edgar Link pending
ex107formofrestrictedstock.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spyre-20240630xex311.htm Edgar Link pending
spyre-20240630xex312.htm Edgar Link pending
spyre-20240630xex321.htm Edgar Link pending
syre-20240630.htm Edgar Link pending
syre-20240630.xsd Edgar Link pending
syre-20240630_def.xml Edgar Link unprocessable
syre-20240630_g1.jpg Edgar Link pending
syre-20240630_g2.jpg Edgar Link pending
syre-20240630_g3.jpg Edgar Link pending
syre-20240630_g4.jpg Edgar Link pending
syre-20240630_g5.jpg Edgar Link pending
syre-20240630_pre.xml Edgar Link unprocessable
syre-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
syre-20240630_lab.xml Edgar Link unprocessable
syre-20240630_cal.xml Edgar Link unprocessable